Last update 01 Nov 2024
Beijing Yimiao Medical Technology Co., Ltd.
Private Company|
2018|
Beijing Shi, China
Last update 01 Nov 2024
Overview
Tags
Neoplasms
Immune System Diseases
Hemic and Lymphatic Diseases
Autologous CAR-T
CAR-T
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
评估IM19 CAR-T细胞治疗复发或难治CD19阳性急性B淋巴细胞白血病的安全性和有效性的I/II期临床研究
[Translation] Phase I/II clinical study to evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of relapsed or refractory CD19-positive acute B-lymphoblastic leukemia
评估IM19 CAR-T细胞治疗复发或难治CD19阳性套细胞淋巴瘤患者的安全性和有效性的I/II期临床研究
[Translation] A phase I/II clinical study to evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma
评估 IM19CAR-T 细胞治疗复发或难治 CD19 阳性侵袭性非霍奇金淋巴瘤患者的安全性和有效性的 I/II 期临床研究
[Translation] A phase I/II clinical study to evaluate the safety and efficacy of IM19CAR-T cells in patients with relapsed or refractory CD19-positive aggressive non-Hodgkin's lymphoma
100 Clinical Results associated with Beijing Yimiao Medical Technology Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Beijing Yimiao Medical Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Beijing Yimiao Medical Technology Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 27 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
1
1
Phase 1 Clinical
Phase 2 Clinical
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free